Literature DB >> 24671921

Linguistic validation into 20 languages and content validity of the rheumatoid arthritis-specific Work Productivity and Activity Impairment questionnaire.

Jérémy Lambert1, Brian B Hansen, Benoit Arnould, Géraldine Grataloup, Isabelle Guillemin, Lise Højbjerre, Martin Strandberg-Larsen, Margaret C Reilly.   

Abstract

BACKGROUND: Impairments in work productivity and daily activities contribute to the burden of rheumatoid arthritis (RA). It is thus essential to use an instrument assessing both work and daily activity impairments when studying the full impact of RA on individuals. The Work Productivity and Activity Impairment (WPAI) questionnaire is such an instrument.
OBJECTIVE: This study aims to linguistically validate the RA-specific WPAI (WPAI:RA) instrument in 20 new languages and to assess its content validity for individuals with RA.
METHODS: The linguistic validation of the questionnaire followed a standard methodology that included comprehension test interviews (n = 5 individuals with RA per language) to assess the relevance, understanding and acceptability of the WPAI:RA. Content validity of the instrument was simultaneously investigated.
RESULTS: Comprehension testing showed that the WPAI:RA questionnaire was well understood similarly across countries; minor changes were made to ensure fidelity to the original concepts and for ease of comprehension. The majority of interviewees (66/93) considered its content comprehensive and appropriate to measure their ability to work and perform daily activities.
CONCLUSION: The WPAI:RA questionnaire is now linguistically validated in 20 new languages [Czech (Czech Republic), Dutch (Belgium), English (Canada and UK), French (Belgium, Canada and France), German (Germany), Hungarian (Hungary), Italian (Italy), Polish (Poland), Portuguese (Brazil), Romanian (Romania), Russian (Russia and Ukraine), Spanish (Argentina, Mexico, Spain and US) and Ukrainian (Ukraine)]. The WPAI:RA questionnaire shows good content validity. It can thus be used in multi-country clinical trials to assess RA-related impact on the patients' ability to work and perform daily activities.

Entities:  

Mesh:

Year:  2014        PMID: 24671921     DOI: 10.1007/s40271-014-0053-4

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  30 in total

Review 1.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  The validity and reproducibility of a work productivity and activity impairment instrument.

Authors:  M C Reilly; A S Zbrozek; E M Dukes
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

3.  Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.

Authors:  B G Feagan; M C Reilly; L Gerlier; Y Brabant; M Brown; S Schreiber
Journal:  Aliment Pharmacol Ther       Date:  2010-03-18       Impact factor: 8.171

4.  Preventing work disability among employees with rheumatoid arthritis: what medical professionals can learn from the patients' perspective.

Authors:  Inge Varekamp; Joke A Haafkens; Sarah I Detaille; Paul P Tak; Frank J H van Dijk
Journal:  Arthritis Rheum       Date:  2005-12-15

5.  Productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments.

Authors:  Wei Zhang; Monique A M Gignac; Dorcas Beaton; Kenneth Tang; Aslam H Anis
Journal:  J Rheumatol       Date:  2010-07-01       Impact factor: 4.666

6.  Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA.

Authors:  Louise M A Braakman-Jansen; Erik Taal; Ina H Kuper; Mart A F J van de Laar
Journal:  Rheumatology (Oxford)       Date:  2011-12-16       Impact factor: 7.580

7.  The validity and accuracy of the Work Productivity and Activity Impairment questionnaire--irritable bowel syndrome version (WPAI:IBS).

Authors:  M C Reilly; A Bracco; J-F Ricci; J Santoro; T Stevens
Journal:  Aliment Pharmacol Ther       Date:  2004-08-15       Impact factor: 8.171

8.  Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

Authors:  Dennis A Revicki; Mary Kaye Willian; Alan Menter; Kenneth B Gordon; Alexa B Kimball; Craig L Leonardi; Richard G Langley; Miriam Kimel; Martin Okun
Journal:  J Dermatolog Treat       Date:  2007       Impact factor: 3.359

9.  Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis.

Authors:  Margaret C Reilly; Katherine L Gooch; Robert L Wong; Hartmut Kupper; Désirée van der Heijde
Journal:  Rheumatology (Oxford)       Date:  2010-01-25       Impact factor: 7.580

10.  The significance of presenteeism for the value of lost production: the case of rheumatoid arthritis.

Authors:  Rikke Søgaard; Jan Sørensen; Louise Linde; Merete L Hetland
Journal:  Clinicoecon Outcomes Res       Date:  2010-07-16
View more
  2 in total

1.  On-site multi-component intervention to improve productivity and reduce the economic and personal burden of neck pain in Swiss office-workers (NEXpro): protocol for a cluster-randomized controlled trial.

Authors:  Andrea M Aegerter; Manja Deforth; Venerina Johnston; Markus J Ernst; Thomas Volken; Hannu Luomajoki; Beatrice Brunner; Julia Dratva; Gisela Sjøgaard; Achim Elfering; Markus Melloh
Journal:  BMC Musculoskelet Disord       Date:  2020-06-19       Impact factor: 2.362

2.  Large country differences in work outcomes in patients with RA - an analysis in the multinational study COMORA.

Authors:  Antje van der Zee-Neuen; Polina Putrik; Sofia Ramiro; Andras P Keszei; Ihsane Hmamouchi; Maxime Dougados; Annelies Boonen
Journal:  Arthritis Res Ther       Date:  2017-09-29       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.